Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04575766 · ClinicalTrials.gov registry record · Phase 1
A Study of FT-7051 in Men With MCRPC
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04575766 is a Phase 1 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 25 participants.
The verdict
NCT04575766, a Phase 1 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label study that will evaluate the safety and tolerability of FT-7051 and determine the recommended Phase 2 dose (RP2D) as well as pharmacokinetics (PK), preliminary anti-tumor activity, and pharmacodynamics (PD) of FT-7051 in men with metastatic castration-resistant prostate cancer who have progressed despite prior therapy and had been treated with at least one potent anti-androgen therapy. The starting dose, 25 mg once daily (QD), of FT-7051 administered discontinuously (21 days on/7 days off) in 28-day cycles.
Interventions
- DRUG FT-7051
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-12-30 |
| Est. Completion | 2022-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04575766
The ClinicalTrials.gov registry entry for NCT04575766 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FT-7051 is the first listed.
NCT04575766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04575766 about?
NCT04575766 is a clinical study titled "A Study of FT-7051 in Men With MCRPC". This is a Phase 1, open-label study that will evaluate the safety and tolerability of FT-7051 and determine the recommended Phase 2 dose (RP2D) as well as pharmacokinetics (PK), preliminary anti-tumor activity, and pharmacodynamics (PD) of FT-7051 in men with metastatic castration-resistant prostate...
What is the current status of trial NCT04575766?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2020-12-30. Estimated completion is 2022-11-15.
What interventions are being tested in trial NCT04575766?
The interventions under investigation include: FT-7051 (DRUG).
Who is sponsoring clinical trial NCT04575766?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.